JP2010053138A - Obesity-preventing/improving agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a material for an obesity-preventing/improving agent exhibiting the effects of preventing and improving onset of various lifestyle-related diseases such as hyperlipemia, and also for materials of foods, medicinal products and the like, having high safety and wide application and scarcely impairing texture. <P>SOLUTION: The invention relates to an obesity-preventing/improving agent comprising a hydroxypropylated starch as an active ingredient. There is disclosed the use of the hydroxypropylated starch for obesity prevention and improvement (excluding the medical use for humans). <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a material that has a preventive / ameliorating action on lifestyle-related diseases such as obesity and diabetes and is useful as a food or a medicine.

  In recent years, in addition to excessive intake of energy (increased intake of fat and sucrose) accompanying the Westernization of Japanese dietary habits, exercise deficits overlap, and lifestyle-related diseases such as obesity and diabetes continue to increase. Yes. From such a social background, prevention and improvement measures for obesity and diabetes are extremely important.

  In order to prevent and ameliorate obesity and diabetes, ingestion of a low-calorie diet or a low-fat diet is a method generally proposed by nutritionists. In recent years, water-insoluble dietary fibers such as wheat bran, water-soluble dietary fibers such as indigestible dextrin, and digestion-resistant starches such as high amylose starch, respectively, promote lipid excretion (for example, see Non-Patent Document 1), sugar absorption It has an inhibitory action (for example, see Non-Patent Document 2), a blood neutral fat lowering action (for example, see Non-Patent Document 3), or a glucose tolerance improving action (for example, Non-Patent Document 4, Patent Document 5 and Non-Patent Document 6) have been reported, and are considered to be effective in preventing and improving obesity and preventing and improving diabetes.

  In addition, since a rapid increase in blood lipid after meal is thought to promote fat accumulation, an approach to suppress postprandial hyperlipidemia (increase in blood triglyceride) in the prevention and improvement of obesity. In recent years, chitansan gum, alginic acid propylene glycol ester (for example, see Patent Document 1) and chitosan (for example, see Patent Document 2) have been reported as safe and effective lipid absorption inhibitors.

  However, the above-mentioned low-calorie diet or low-fat diet may have some temporary effects on weight loss, but it is rejected by the person after a long period of time due to the monotonous flavor of the food that makes it. It is difficult to maintain this for a long time. In addition, in order for food materials such as the conventional water-insoluble dietary fiber, water-soluble dietary fiber, and digestion-resistant starch to exhibit the above physiological effects, they must be ingested at a high dose for a long period of time. Moreover, even if the physiological action is expressed, suppression of obesity has not been confirmed. Furthermore, when foods and drinks are produced using them, it is often difficult to contain them in foods in sufficient amounts because they often impair the texture of foods and drinks, such as appearance, taste, texture, and smoothness. However, there are problems that application fields are limited, and that it is difficult to continue taking such foods and drinks for a long time.

Hydroxypropylated starch is known to have high transparency, excellent film-forming properties, low-temperature storage stability, and high freezing / thawing stability. In the US, it is approved for food use by the FDA. (For example, see Non-Patent Document 7).
However, it has not been known so far that hydroxypropylated starch has an effect of preventing or improving the onset of lifestyle-related diseases such as obesity and diabetes.

JP-A-5-186356 JP-A-3-290170

Am J Clin Nutr 1978 31 (10 Suppl): 521-529 Journal of the Japan Endocrine Society 1992 68 (6): 623-35 Am J Clin Nutr 1989 49 (2): 337-44 Acta Paediatr Hung 1985 26 (1): 75-7 J Endocrinol 1995 144 (3): 533-8 Am J Clin Nutr 1989 49 (2): 337-44 Journal of Japanese Society for Home Economics 1998 49 (9): 985-992

  The present invention exhibits the effect of preventing and improving the onset of various lifestyle-related diseases such as obesity prevention / amelioration agent, prevention / amelioration of hyperlipidemia, etc. It is related to providing materials such as foods and pharmaceuticals that are less likely to damage food.

  The present inventors have searched for a material having physical properties different from those of dietary fibers represented by conventional resistant starch, cellulose and resistant dextrin, and also has an effect of suppressing and improving the progression of obesity and diabetes. As a result, hydroxypropylated starch has various physiological effects including obesity-inhibiting action with a small amount of intake, and exhibits foods and pharmaceutical materials that exhibit prevention and improvement effects on lifestyle-related diseases such as obesity and diabetes As found useful.

  That is, the present invention provides an obesity preventive / ameliorating agent, a visceral fat accumulation inhibitor, a blood sugar level rise inhibitor, a blood triglyceride rise inhibitor, and a diabetes preventive / ameliorating agent comprising hydroxypropylated starch as an active ingredient. Is.

  The obesity prevention / amelioration agent of the present invention includes various prevention and improvement of obesity, prevention and improvement of hyperlipidemia, prevention of heart diseases such as heart failure, prevention of thrombosis, prevention of colon cancer and rectal cancer, etc. It is useful as a food, medicine, etc. because it can exert the effect of preventing and improving the onset of lifestyle-related diseases. In particular, hydroxypropylated starch, which is an active ingredient, has excellent safety to the human body because it uses starch as a raw material, and it is easy to gelatinize, so it is widely applicable to foods and drinks and blended with foods for specified health use. In that case, it is less likely to damage the texture that they originally have.

The hydroxypropylated starch of the present invention can be obtained by hydroxypropylating starch or modified starch by a conventional method. Specifically, it can be obtained by reacting propylene oxide with starch.
National Frigex (from Tapioca, National Starch and Chemical), National 1658 (from Corn, National Starch and Chemical), Thermal Flow (from Waxy Corn, National Starch and Chemical), Thermtex (from Waxy Corn, National Commercial products such as Starch and Chemical Co.) can also be used.

  Examples of the raw material starch include waxy corn starch, corn starch, wheat starch, rice starch, glutinous rice starch, potato starch, sweet potato starch, tapioca starch, sago starch and the like. It is more preferable that the content is -100%, more preferably 90-100%, because the paste liquid has high transparency, and when applied to foods and drinks, its appearance is not impaired and the application range is widened. Among these, waxy corn starch and tapioca starch are preferable as the raw material starch.

  The “hydroxypropylated starch” in the present invention includes a hydroxypropylated starch obtained by combining other processing treatments. Processing that can be combined includes esterification of acetic acid, octenyl succinic acid, phosphoric acid, etc., etherification by carboxymethyl etherification other than hydroxypropylation, trimetaphosphate, hexametaphosphate, phosphorus oxychloride, adipic acid , Epichlorohydrin and the like, crosslinking treatment using a conventional crosslinking agent, oxidation treatment, acid treatment, bleaching treatment, wet heat treatment, heat treatment, enzyme treatment, etc. may be mentioned, of which one or more of them may be combined good. Of these, esterification treatment is preferred, and phosphorylation treatment, particularly phosphoric acid crosslinking treatment is preferred. As the degree of phosphorylation treatment, the bound phosphorus content is in the range of 0.0001 to 2%, preferably 0.0001 to 0.5%, more preferably 0.0001 to 0.2%. Is preferable from the viewpoint of texture and the like.

  As the degree of hydroxypropylation, the degree of substitution (number of hydroxypropyl groups per anhydroglucose residue in starch) is preferably 0.001 to 1, more preferably 0.05 to 0.5. Yes, and preferably 0.1 to 0.3.

  The hydroxypropylated starch can be produced from starch with high purity and relatively low cost by a simple process. Moreover, it is highly safe and has no sense of incongruity when used in various foods, medicines, pet foods, etc., as compared with conventional dietary fiber and resistant starch. Moreover, since it is excellent in refrigeration resistance, it can have the advantage that alteration by thaw is unlikely to occur.

And since the hydroxypropylated starch has an obesity-inhibiting action in which the body weight and visceral fat amount are significantly reduced, as shown in the examples below, the prevention of hyperlipidemia caused by obesity. It can exert effects such as prevention of heart diseases such as heart failure, prevention of thrombosis, prevention of hypertension and the like. Second, it has an effect of suppressing postprandial hyperlipidemia, that is, an increase in blood triglyceride concentration after a meal. Thirdly, postprandial hyperglycemia, that is, has an action of suppressing a rapid increase in blood sugar level after meals, and has an action of suppressing an increase in blood sugar level at the steady state, such as diabetes and various complications resulting therefrom, such as It can exert effects such as preventing cataracts, periodontal disease, diabetic nephropathy, retinopathy, and neuropathy.
Therefore, the hydroxypropylated starch of the present invention is used as an obesity prevention / amelioration agent, blood triglyceride elevation inhibitor, blood sugar level elevation inhibitor, diabetes prevention / amelioration agent (hereinafter referred to as obesity prevention / amelioration agent, etc.) It can be a material for human or animal food or medicine.

The agent for preventing / ameliorating obesity of the present invention can be administered in combination with one or more hydroxypropylated starches to humans and animals as well as in various foods, medicines, pet foods and the like. As food, it can be applied to beauty foods, foods for the sick, and foods for specified health use based on physiological functions such as body fat accumulation suppression and blood sugar level increase suppression. When used as a pharmaceutical, for example, oral solid preparations such as tablets and granules, and oral liquid preparations such as oral liquids and syrups can be used.
When preparing an oral solid preparation, an excipient, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a corrigent, a corrigent and the like are added to the hydroxypropylated starch of the present invention. Thereafter, tablets, coated tablets, granules, powders, capsules and the like can be produced by conventional methods. Moreover, when preparing a liquid preparation for oral use, a liquid preparation, a syrup, an elixir, etc. can be manufactured by a conventional method by adding a corrigent, a buffer, a stabilizer, a corrigent and the like.

  The blending amount of the hydroxypropylated starch to be blended in each of the above preparations is usually 5 to 100% by weight, preferably 20 to 100% by weight, and more preferably 30 to 100% by weight.

  The dose (effective intake) of the obesity preventing / ameliorating agent of the present invention is preferably 0.01 g / kg body weight or more per day, particularly 0.1 g / kg body weight or more, more preferably 0.4 g / kg body weight. The above is preferable.

Test Example 1 Obesity-inhibiting action and blood glucose level-inhibiting action of hydroxypropylated starch Tapioca starch and waxy corn starch were obtained from National Starch and Chemical Co., Ltd. As a hydroxypropylated starch, commercially available National Frigex (from tapioca, National Starch and Chemical Co.), Thermoflow (hydroxypropylation degree (DS value) = 0.154, phosphorylation degree (bound phosphorus content) = 0.004%, derived from waxy corn, National Starch and Chemical Co.).
The above starch was suspended in distilled water to 50% by weight, autoclaved (wet heat treatment) at 120 ° C. for 15 minutes, and then freeze-dried to prepare a test starch that was pregelatinized.

  Mice (C57BL / 6J male, 6-week-old) were grouped as 10 animals, and were bred using various pregelatinized starches and a diet prepared according to the formulation shown in Table 1. After 24 weeks of breeding, the mice were bled and sacrificed, and the blood glucose level and visceral fat weight were measured. Table 2 shows the body weights of the mice after 10 weeks and 23 weeks of breeding, and the visceral fat weight and blood glucose level after 24 weeks of breeding.

From the results of Table 2, in mice that ingested a feed containing 5% of hydroxypropylated starch (derived from tapioca and waxy corn), the body weight, In addition, it can be seen that the visceral fat weight is significantly low and an obesity suppressing effect is observed.
Moreover, in the mouse | mouth which ingested the high fat diet which mix | blended 5% of tapioca or waxy corn starch, the blood glucose level at the stationary time was high compared with the mouse | mouth which ingested the low fat diet. However, in mice that ingested high-fat diet containing 5% of hydroxypropylated tapioca or waxy corn starch, compared to mice that ingested feed containing the corresponding raw starch (from tapioca and waxy corn), It can be seen that the steady-state blood glucose level is low and an effect of suppressing the increase in blood glucose level is observed.

Test Example 2 Obesity-inhibiting action of hydroxypropylated starch Tapioca starch and waxy corn starch were obtained from National Starch and Chemical Co., Ltd. As the hydroxypropylated starch, National Frigex (from tapioca, National Starch and Chemical Co.), Thermoflow (from waxy corn, National Starch and Chemical Co.), and the above tapioca starch or waxy corn starch were used as J Nutr 1998 128 ( 5): Hydroxypropylated by the method described in 848-54. As the resistant starch, a commercially available product, Fibose (derived from high amylose corn, Lot. 11785), was obtained from Nissho Chemical Co., Ltd.
The above starch was suspended in distilled water to 50% by weight, autoclaved (wet heat treatment) at 120 ° C. for 15 minutes, and then freeze-dried to prepare a test starch that was pregelatinized. Indigestible dextrin was obtained from Matsutani Chemical Co., Ltd., and cellulose was obtained from Oriental Yeast Co., Ltd.

  10 mice per group (C57BL / 6J male, 6 weeks old) were bred for 13 weeks using various pregelatinized starches, indigestible dextrin, and cellulose, prepared using the diet shown in Table 1, Body weight was measured every week. The results are shown in Table 3.

  From the results in Table 3, the mice that ingested a feed containing 5% of hydroxypropylated starch (derived from tapioca and waxy corn) had a weight that was higher than that of the mice that ingested the feed containing the corresponding raw material starch. Significantly low, obesity-inhibiting effect is observed, but indigestible starch (derived from high amylose corn), indigestible dextrin, which is a water-soluble dietary fiber, and cellulose, which is a water-insoluble dietary fiber, do not have an obesity-inhibiting effect I understand that.

Test Example 3 Postprandial blood triglyceride elevation inhibitory action of hydroxypropylated starch Tapioca starch and waxy corn starch were obtained from National Starch and Chemical Co., Ltd. As the hydroxypropylated starch, National Frigex (from tapioca, National Starch and Chemical Co.) and Therm Flow (from waxy corn, National Starch and Chemical Co.) were used. As the resistant starch, a commercially available product, Fibose (derived from high amylose corn, Lot. 11785), was obtained from Nissho Chemical Co., Ltd.
The above starch was suspended in distilled water so as to be 5% by weight, and autoclaved (wet heat treatment) at 120 ° C. for 15 minutes to prepare a pregelatinized test starch.

  A group of 9 SD rats (male, 8 weeks old), 0.15 g of various pregelatinized starches, 0.2 g of corn oil, 0.3 g of sodium taurocholate, 0.052 g of bovine serum albumin, and a sonde needle And administered orally. After 0, 30, 60, 120, and 240 minutes, blood was collected from the jugular vein to prepare plasma. Triglycerides in plasma were measured using Triglyceride Test Wako (Wako Pure Chemical Industries, Ltd.). The results are shown in Table 4.

  From the results of Table 4, in rats that were orally administered a lipid emulsion containing hydroxypropylated starch (derived from tapioca and waxy corn), a lipid emulsion containing the corresponding raw starch or resistant starch (Fibosu) was orally administered. Compared with rats, the increase in plasma triglyceride concentration was significantly lower, and a blood triglyceride increase inhibitory effect was observed.

Test Example 4 Postprandial Blood Glucose Level Suppressing Action of Hydroxypropylated Starch Tapioca starch, corn starch, and waxy corn starch were obtained from National Starch and Chemical Company. Hydroxypropylated starches include National Frigex (from Tapioca, National Starch and Chemical), 1658 (from Corn, National Starch and Chemical), Therm Flow (from waxy corn, National Starch and Chemical), Thermtex (From waxy corn, National Starch and Chemical Co.) was used. As resistant starch, high amylose corn starch and commercial product Phybose (derived from high amylose corn, Lot. 11785) were obtained from Nissho Chemical Co., Ltd.
The above starch was suspended in distilled water to 5% by weight, autoclaved (wet heat treatment) at 120 ° C. for 15 minutes, and then allowed to cool to room temperature.
The dietary fiber content after the starch treatment was measured according to the method of Akerberg AK et al. (J Nutr. 128: 651-660, 1998).

The above-mentioned starch treatment solution was orally administered to mice (C57BL / 6J male, 6 weeks old, 6 mice per group) so as to be 2 mg starch / g body weight, and blood was collected from the tail vein after 0, 30, 60, 120 minutes. The blood glucose level was then measured with a simple blood glucose level measurement system (Accucheck Comfort, Roche Diagnostics Co., Ltd.).
Table 5 shows the dietary fiber content of each test starch, the maximum blood sugar level 2 hours after oral administration, and the area under the blood sugar curve.

  From the results shown in Table 5, in mice to which hydroxypropylated starch (derived from tapioca and waxy corn) was orally administered, the increase in blood glucose level was significantly lower than that of the corresponding raw material starch, which is representative of high amylose corn starch. Although the dietary fiber content was significantly lower than the resistant starch, the same postprandial blood glucose level inhibitory effect was observed.

Claims (15)

  Use of hydroxypropylated starch as an active ingredient in foods for the prevention and improvement of obesity.   Use of hydroxypropylated starch to prevent and improve obesity (except for use as a human medicine).   Use of hydroxypropylated starch as an obesity prevention / amelioration agent (except for use as a human medicine).   Use of hydroxypropylated starch as an active ingredient in foods for inhibiting visceral fat accumulation.   Use of hydroxypropylated starch to suppress visceral fat accumulation (except for use as a human medicine).   Use of hydroxypropylated starch as a visceral fat accumulation inhibitor (except for use as a human medicine).   Use of hydroxypropylated starch as an active ingredient in foods for suppressing blood sugar elevation.   Use of hydroxypropylated starch to suppress an increase in blood glucose level (except for use as a human medicine).   Use of hydroxypropylated starch as an inhibitor of blood glucose level elevation (except for use as a human medicine).   Use of hydroxypropylated starch as an active ingredient in foods for inhibiting blood triglyceride elevation.   Use of hydroxypropylated starch to suppress blood triglyceride elevation (except for use as a human medicine).   Use of hydroxypropylated starch as an inhibitor of blood triglyceride elevation (except for use as a human medicine).   Use of hydroxypropylated starch as an active ingredient in foods for the prevention and / or improvement of diabetes.   Use of hydroxypropylated starch for diabetes prevention / improvement (except for use as a human medicine).   Use of hydroxypropylated starch as a preventive / ameliorating agent for diabetes (except for use as a human medicine).